v3.26.1
Pay vs Performance Disclosure - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table Pay Versus Performance
As required by Item 402(v) of Regulation S-K, the following table and accompanying footnotes and discussion provide
certain information regarding executive compensation of our principal executive officer (“PEO”) and non-PEO NEOs
(“Non-PEO NEOs”) and measures of Company performance for the years presented. Except where expressly stated, the
information presented below was not considered by the Compensation Committee in structuring our executive
compensation program for the years presented, and the reader should instead refer to the section “Compensation
Discussion and Analysis” for a description of the philosophy, objectives, and structure of our pay program.
A
B
C
D
E
F
G
H
I
Value of Initial Fixed
$100 Investment
Based On:
Year
Summary
Compensation
Table Total for
PEO ($)1
Compensation
“Actually Paid”
to PEO ($)1,2,3
Average Summary
Compensation
Table
Total for Non-PEO
NEOs ($)1
Average
Compensation
“Actually Paid”
to
Non-PEO NEOs
($)1,2,3
TSR ($)
Peer Group
TSR ($)4
Net Income ($)
Stock
Price
($)5
2025
7,280,549
38,950,031
7,730,237
14,697,023
159.77
200.89
4,504,900,000
771.87
2024
6,823,034
(37,696,190)
6,073,090
(9,153,791)
147.45
156.19
4,412,600,000
712.33
2023
8,184,338
141,071,193
6,713,442
46,896,425
181.80
143.88
3,953,600,000
878.29
2022
7,004,069
98,786,583
8,061,639
32,174,465
149.34
138.51
4,338,400,000
721.49
2021
6,470,514
123,744,652
7,548,928
40,168,860
130.72
124.39
8,075,300,000
631.52
       
Company Selected Measure Name stock price        
Named Executive Officers, Footnote Leonard S. Schleifer, M.D., Ph.D. was our PEO for each year presented. George D. Yancopoulos, M.D., Ph.D., Daniel P. Van Plew, and
Andrew J. Murphy, Ph.D. were among the Non-PEO NEOs for each year presented along with Robert E. Landry for 2021 through 2024,
Joseph J. LaRosa for 2021 and 2025, Marion McCourt for 2022, and Christopher Fenimore for 2024 and 2025.
       
Peer Group Issuers, Footnote The Peer Group TSR shown in this table utilizes the NASDAQ US Benchmark Pharmaceuticals Total Return Index (“NQ US Pharma Index”), which we
also utilized in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Reports on Form 10-K for the years
reflected in the table above. The comparison assumes $100 was invested for the period starting December 31, 2020 through December 31 of the
applicable fiscal year in each of the Company’s common stock and the NQ US Pharma Index. All dollar values assume reinvestment of the pre-tax value
of dividends paid by companies included in the NQ US Pharma Index. The historical stock price performance of our common stock shown is not
necessarily indicative of future stock price performance.
       
PEO Total Compensation Amount $ 7,280,549 $ 6,823,034 $ 8,184,338 $ 7,004,069 $ 6,470,514
PEO Actually Paid Compensation Amount $ 38,950,031 (37,696,190) 141,071,193 98,786,583 123,744,652
Adjustment To PEO Compensation, Footnote
Year
Summary Compensation
Table Total for PEO ($)
Exclusion of Stock Awards
and Option Awards from
Summary Compensation
Table for PEO ($)
Inclusion of Item 402(v)
Equity Award Values for
PEO ($)
Compensation “Actually
Paid” to PEO ($)
2025
7,280,549
0
31,669,482
38,950,031
Year
Year-End Fair
Value of Equity
Awards Granted
During Year
That Remained
Unvested as of
Last Day of Year
for PEO ($)
Change in
Fair Value from
Last Day of
Prior Year to
Last Day of Year
of Unvested
Equity Awards
for PEO ($)
Vesting-Date
Fair Value of
Equity Awards
Granted During
Year that
Vested During
Year for PEO ($)
Change in
Fair Value from
Last Day of
Prior Year to
Vesting Date of
Unvested Equity
Awards that
Vested During
Year for PEO ($)
Fair Value
at Last Day
of Prior Year
of Equity
Awards
Forfeited
During Year
for PEO ($)
Value of Dividends
or Other Earnings
Paid on Stock or
Option Awards
Not Otherwise
Included
for PEO ($)
Total—Inclusion
of Equity Values
for PEO ($)
2025
0
0
0
31,669,482
0
0
31,669,482
       
Non-PEO NEO Average Total Compensation Amount $ 7,730,237 6,073,090 6,713,442 8,061,639 7,548,928
Non-PEO NEO Average Compensation Actually Paid Amount $ 14,697,023 (9,153,791) 46,896,425 32,174,465 40,168,860
Adjustment to Non-PEO NEO Compensation Footnote
Year
Average Summary
Compensation Table Total for
Non-PEO NEOs ($)
Exclusion of Stock Awards
and Option Awards from
Summary Compensation
Table for Non-PEO NEOs ($)
Inclusion of Item 402(v)
Equity Award Values for
Non-PEO NEOs ($)
Average Compensation
“Actually Paid” to
Non-PEO NEOs ($)
2025
7,730,237
(4,699,568)
11,666,354
14,697,023
Year
Average
Year-End
Fair Value of
Equity Awards
Granted During
Year That
Remained
Unvested
as of Last
Day of Year
for Non-PEO
NEOs ($)
Average Change
in Fair Value
from Last Day
of Prior Year to
Last Day of
Year of
Unvested
Equity Awards
for Non-PEO
NEOs ($)
Average
Vesting-Date
Fair Value
of Equity
Awards Granted
During Year
that Vested
During Year
for Non-PEO
NEOs ($)
Average Change
in Fair Value
from Last Day
of Prior Year
to Vesting Date
of Unvested
Equity Awards
that Vested
During Year for
Non-PEO
NEOs ($)
Average Fair
Value at
Last Day of
Prior Year of
Equity Awards
Forfeited During
Year for
Non-PEO
NEOs ($)
Average Value
of Dividends
or Other
Earnings Paid
on Stock or
Option Awards
Not Otherwise
Included
for Non- PEO
NEOs ($)
Total—Average
Inclusion of
Equity Values
for Non-PEO
NEOs ($)
2025
5,237,392
356,324
0
6,072,638
0
0
11,666,354
       
Compensation Actually Paid vs. Net Income Description of Relationship Between NEO Compensation “Actually Paid” and Net Income
The following chart sets forth the relationship between Compensation “Actually Paid” to our PEO, the average of
Compensation “Actually Paid” to our Non-PEO NEOs, and our net income during years 2021 through 2025, each as
set forth in the table above.
PEO and Average NEO Compensation “Actually Paid” Versus Regeneron Net Income, 2021-2025
8796093037527
Fiscal Year
02_REGN_PXY_2026_PEO.gif
PEO Compensation “Actually Paid”
02_REGN_PXY_2026_Non-PEO.gif
Average Non-PEO NEO Compensation “Actually Paid”
02_REGN_PXY_2026_NQ-01.gif
REGN Net Income
       
Compensation Actually Paid vs. Company Selected Measure Description of Relationship Between NEO Compensation “Actually Paid” and Stock Price
The following chart sets forth the relationship between Compensation “Actually Paid” to our PEO, the average of
Compensation “Actually Paid” to our Non-PEO NEOs, and the closing price of our common stock on the last trading day of
years 2021 through 2025, each as set forth in the table above.
PEO and Average Non-PEO NEO Compensation “Actually Paid” Versus Regeneron Stock Price, 2021-2025
8796093037575
Fiscal Year
02_REGN_PXY_2026_PEO.gif
PEO Compensation “Actually Paid”
02_REGN_PXY_2026_Non-PEO.gif
Average Non-PEO NEO Compensation “Actually Paid”
02_REGN_PXY_2026_NQ-01.gif
REGN Stock Price
       
Total Shareholder Return Vs Peer Group Description of Relationship Between NEO Compensation “Actually Paid” and Total
Shareholder Return
The following chart sets forth the relationship between Compensation “Actually Paid” to our PEO, the average of
Compensation “Actually Paid” to our Non-PEO NEOs, each as set forth in the Table above, and the Company’s cumulative
TSR over the five-year period from 2021 through 2025. The following chart also compares the Company’s cumulative TSR
over the five-year period from 2021 through 2025 to that of the NQ US Pharma Index over the same time period.
PEO and Average Non-PEO NEO Compensation “Actually Paid” Versus Regeneron TSR and
Peer Group TSR, 2021-2025
8796093037470
Fiscal Year
02_REGN_PXY_2026_PEO.gif
PEO Compensation “Actually Paid”
02_REGN_PXY_2026_Non-PEO.gif
Average Non-PEO NEO Compensation “Actually Paid”
02_REGN_PXY_2026_NQ-01.gif
REGN TSR
02_REGN_PXY_2026_LegendNQUS.jpg
NQ US Pharma Total Return Index TSR
       
Tabular List, Table 2025 Tabular List of Most Important Financial and Non-Financial Performance Measures
The following table presents the financial and non-financial performance measures that the Company considers to have
been the most important in linking Compensation “Actually Paid” to our PEO and our Non-PEO NEOs in 2025 to Company
performance. The measures in this table are not ranked.
Stock Price
Regulatory submissions for new products or indications
TSR
Positive data readouts
Non-GAAP diluted EPS
New Investigational New Drug Applications
Approvals of new products or indications
       
Total Shareholder Return Amount $ 159.77 147.45 181.80 149.34 130.72
Peer Group Total Shareholder Return Amount 200.89 156.19 143.88 138.51 124.39
Net Income (Loss) $ 4,504,900,000 $ 4,412,600,000 $ 3,953,600,000 $ 4,338,400,000 $ 8,075,300,000
Company Selected Measure Amount 771.87 712.33 878.29 721.49 631.52
PEO Name Leonard S. Schleifer Leonard S. Schleifer Leonard S. Schleifer Leonard S. Schleifer Leonard S. Schleifer
Measure:: 1          
Pay vs Performance Disclosure          
Name Stock Price        
Measure:: 2          
Pay vs Performance Disclosure          
Name TSR        
Measure:: 3          
Pay vs Performance Disclosure          
Name Non-GAAP diluted EPS        
Measure:: 4          
Pay vs Performance Disclosure          
Name Approvals of new products or indications        
Measure:: 5          
Pay vs Performance Disclosure          
Name Regulatory submissions for new products or indications        
Measure:: 6          
Pay vs Performance Disclosure          
Name Positive data readouts        
Measure:: 7          
Pay vs Performance Disclosure          
Name New Investigational New Drug Applications        
PEO | Exclusion of Stock Awards and Option Awards from Summary Compensation Table for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 0        
PEO | Inclusion of Item 402(v) Equity Award Values for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 31,669,482        
PEO | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 31,669,482        
PEO | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Value of Dividends or Other Earnings Paid on Stock or Option Awards Not Otherwise Included for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Total—Inclusion of Equity Values for PEO ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 31,669,482        
Non-PEO NEO | Exclusion of Stock Awards and Option Awards from Summary Compensation Table for Non-PEO NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (4,699,568)        
Non-PEO NEO | Inclusion of Item 402(v) Equity Award Values for Non-PEO NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 11,666,354        
Non-PEO NEO | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 5,237,392        
Non-PEO NEO | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 356,324        
Non-PEO NEO | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 6,072,638        
Non-PEO NEO | Average Fair
Value at Last Day of Prior Year of
Equity Awards
Forfeited During
Year for Non-PEO
NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Average Value
of Dividends or Other Earnings Paid on Stock or
Option Awards
Not Otherwise
Included for Non- PEO NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Total—Average
Inclusion of
Equity Values
for Non-PEO
NEOs ($) [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 11,666,354